Abstract: A method of wireless communication by a user equipment (UE) supporting multiple subscriptions, includes camping on a first cell of a first radio access technology (RAT) with a first data subscription, and camping on a second cell of a second RAT with a second data subscription. The method also includes triggering a transition to the first cell of the first RAT for the second data subscription. The method further includes performing, with the first data subscription, activities on behalf of the second data subscription.

Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.

Abstract: Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound has a high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

Abstract: Provided are a crystalline form of a compound represented by formula A, the crystalline form being crystalline form I, crystalline form II, crystalline form III, crystalline form IV, crystalline form V, crystalline form VI, crystalline form VII, crystalline form VIII or crystalline form IX, a preparation method therefor, a composition thereof, and an application thereof in the preparation of a P2X3 receptor antagonist or an application thereof in the preparation of drugs preventing and/or treating pains, urinary tract illness or respiratory system illness. The compound has high P2X3 antagonist activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

Abstract: Disclosed is a heterocyclic compound as represented by formula (I), a tautomer thereof, or a pharmaceutically acceptable salt thereof. The compound has better inhibitory activity on TRPC5, has good metabolic stability in liver micro-particles, and has good clinical pharmacokinetic properties.

Abstract: A ROCK inhibitor represented by formula (I), and a preparation method therefor and a use thereof are provided. The ROCK inhibitor has excellent ROCK inhibition activity, particularly shows good selective inhibition on ROCK2 kinase, has good safety and metabolic stability, and is high in bioavailability. The preparation method for the ROCK inhibitor is simple, and the ROCK inhibitor is easy to purify, and therefore has a good application prospect.

Abstract: Compositions and methods to 3D print high quality inorganic nanostructures from a nanocomposite ink using two-photon polymerization are provided. Methods provide capability for 3D printing inorganic silica structures with sub-200 nm resolution with controlled crystallinity and doping. The final 3D printed inorganic product is shown to be pure SiO2, which can be in either glass or crystalline polymorph depending on the sintering process. The 3D printed fabricated products also show remarkable optical performance with the 3D printed micro-toroid optical resonators having quality factors (Q) over 104. For optical applications, doping and co-doping of rare earth salts such as Er3+, Tm3+, Yb3+, Eu3+ and Nd3+ can be directly implemented in the printed SiO2 structures.

Abstract: A compound containing a benzene ring as shown in formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotopic compound thereof, a crystal form thereof, a nitrogen oxide thereof, and a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof are provided. The compound has high P2X4 antagonistic activity, good selectivity, low toxicity and good metabolic stability.

Abstract: A multifunctional sofa includes armrest assemblies and seat units. A middle armrest is arranged between the adjacent seat units, and a front end of the middle armrest is provided with a cupholder. An upper end surface of the cupholder is provided with a cup slot, and an outer cover is also provided outside the cupholder. The outer cover may rotate relative to the cupholder to allow the one cup slot to be unfolded or folded. A movable function rack capable of rotating outwards relative to the armrest assembly is arranged in each of armrest assemblies. The movable function rack is provided with a function table. In the hidden position, the movable function rack is entirely located in the accommodating groove. In the use position, the movable function rack rotates outwards from the accommodating groove to protrude from the armrest assembly, and the function table is exposed outside.

Abstract: Methods of making hexagonal boron nitride coatings upon stainless steel and other ferrous metal/alloy materials, compositions thereof, and methods of using same, such as in electrothermal membrane distillation systems using hexagonal boron nitride coated metal mesh.

Abstract: Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen oxide, a solvate, or a solvate of the pharmaceutically acceptable salt thereof. The fused ring compound of the present invention has high P2X4 antagonistic activity, excellent selectivity, low toxicity and excellent metabolic stability.

Abstract: A compound of formula (I), and racemates, stereoisomers, tautomers, isotopic markers, solvates, polymorphs and oxynitrides of the compound, or a pharmaceutically acceptable salt thereof can be used as JNK inhibitors. A method for preparing the compound of formula (I) and a pharmaceutical composition comprising the compound of formula (I) are provided. The compound of formula (I) can be used for preparing drugs. The resulting drugs are used for treating diseases that can be treated by inhibiting JNK activity.

Abstract: Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound has a high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

Abstract: The compound represented by formula (I), and racemates, stereoisomers, tautomers, isotopic markers, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts, or prodrugs thereof have ROCK inhibitory activity. The compound represented by formula (1) has good safety, good metabolic stability, and a low risk of potential hepatotoxicity. Further, the compound represented by formula (I) has a simple preparation method and is easy to purify, and therefore has good application prospects.

Abstract: Described is an integrated device for solar-driven water splitting. The integrated device includes cobalt phosphide (CoP) electrodes, series-connected perovskite solar cells (PSCs) encapsulated in a polymer, and a metal film connecting the CoP electrodes with the series-connected PSCs. Also described is a method for forming an integrated device for solar-driven water splitting.

Abstract: A multifunctional sofa includes armrest assemblies and seat units. A middle armrest is arranged between the adjacent seat units, and a front end of the middle armrest is provided with a cupholder. An upper end surface of the cupholder is provided with a cup slot, and an outer cover is also provided outside the cupholder. The outer cover may rotate relative to the cupholder to allow the one cup slot to be unfolded or folded. A movable function rack capable of rotating outwards relative to the armrest assembly is arranged in each of armrest assemblies. The movable function rack is provided with a function table. In the hidden position, the movable function rack is entirely located in the accommodating groove. In the use position, the movable function rack rotates outwards from the accommodating groove to protrude from the armrest assembly, and the function table is exposed outside.

Abstract: Certain compounds are lysophosphatidic acid receptor antagonists have high LPAR1 antagonist activity and selectivity, low toxicity, good metabolic stability, promising pharmaceutical development prospects, and may be used for preventing or treating LPAR1-related diseases or illnesses. The IC50 values of some of the compounds may be as low as 300 nM or below, even 50 nM or below. In addition, CC50 value range of the compounds may be as high as 200 ?M or above. Furthermore, the compounds have good metabolic stability in humans, mice and rats.

Abstract: Certain triazole compounds have good LPAR1 antagonistic activity and selectivity, low toxicity, and good metabolic stability, and can be used for preventing or treating the LPAR1-related disease or disorder. The IC50 value of some triazole compounds can be below 300 nM, even 50 nM. The range of CC50 of the triazole compounds can be greater than 200 ?M. They also show good metabolic stability in human, fancy rats, and house mice.

Abstract: The present disclosure provides a triazole antibacterial derivative and a pharmaceutical composition thereof and a use thereof and in particular relates to a compound represented by the following formula (I), and a racemate, a stereoisomer, a tautomer, an oxynitride or a pharmaceutically acceptable salt thereof: The compound of the present disclosure has a desirable water solubility and can be formulated into an injection for use without adding a cosolvent having a potential safety risk (such as hydroxypropyl-?-cyclodextrin, sulfobutylether-?-cyclodextrin, and the like), facilitating drug administration for patients, and greatly improving clinical safety. The drug can be used even by patients with moderate or severe renal impairment, thereby expanding the application scope of the drug.